EvoGenix Limited Announces Results of Exercise of the Company's Series 1 Options
REHOVOT, ISRAEL--(Marketwire - June 02, 2009) -
| Highlighted Links |
Evogene website |
Ofer Haviv, Evogene's president and CEO, stated: "We welcome this vote of confidence of our investors in the company with the exercise of 99.6% of the issued series 1 options."
About Evogene
Evogene is a world leading developer of improved plant traits. The company's proprietary product development platform combines state of the art computational gene discovery technology (The 'ATHLETE'), plant and field validation capabilities and unique selection systems. Evogene's current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene's website at www.evogene.com.
This press release contains "forward-looking statements." These statements
include words like "may," "expects," "believes," "scheduled" and "intends,"
and they describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Evogene Ltd. to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.